BioStack Raises $9.5 Million Seed Round
Y Combinator-backed BioStack closed a $9.5 million seed round that included Peak XV.
Key Takeaways
- BioStack raised a $9.5 million seed round that included Peak XV.
- Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator also invested.
- The company links hospital records into datasets for medical research and healthcare AI.
- Its network spans the US, India, Brazil and Argentina.
- Sanat Mishra and Parth Patwa founded the company in 2025.
BioStack, a California-based healthcare data startup backed by Y Combinator, has raised $9.5 million in a seed round that included Peak XV. The company turns scattered hospital records into datasets for medical research and healthcare AI.
Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator also took part in the round.
BioStack funding at a glance
| Detail | BioStack |
|---|---|
| Amount | $9.5 million |
| Round | Seed |
| Investor named first | Peak XV |
| Other investors | Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, Y Combinator |
| Sector | Healthcare data and medical AI |
| Use of funds | Expansion in the US and other markets, technology platform, engineering and research hiring |
What BioStack does
BioStack links fragmented clinical records, such as clinical notes, lab results, imaging and medications, into longitudinal patient records. It then builds de-identified datasets that can be used for medical research, biotech development, and training and testing healthcare AI.
The company's network spans the US, India, Brazil and Argentina, and it says it has access to more than 100 million de-identified patient records. It also says its data includes several hundred thousand X-rays, MRI and CT scans and several million telehealth audio transcripts. In India, it helps connect cancer patients with an investigational cancer vaccine programme.
BioStack's journey so far
| When | Milestone |
|---|---|
| 2025 | BioStack is founded by Sanat Mishra and Parth Patwa |
| October 2026 | BioStack announces a $9.5 million seed round that included Peak XV |
Sanat Mishra is co-founder and CEO. He has worked on cancer genomics research at Stanford, Yale, Carnegie Mellon and the Max Planck Institute. Parth Patwa is co-founder and CTO. He was a generative AI scientist at AWS and a researcher at MIT, and has published more than 40 papers.
Sanat Mishra on building the clinical data infrastructure
"We're building the infrastructure that connects all of the clinical information and makes it useful,"
What BioStack says it will do with the money
The company said it will use the funds to expand in the US and other international markets, develop its technology platform and grow its engineering and research teams.
Where BioStack stands after its seed round
BioStack has raised a $9.5 million seed round from Peak XV and seven other investors, including Y Combinator. It works with hospitals and has a network across the US, India, Brazil and Argentina. The company said the new funds will go towards expansion, its technology platform and hiring in engineering and research.
More funding news
Frequently Asked Questions
How much did BioStack raise?
Which investors backed BioStack's round?
What does BioStack do?
Who founded BioStack?
How will BioStack use the funding?
Who else invested in BioStack's seed round?
How many patient records does BioStack say it can access?
Which countries does BioStack's network cover?
How does BioStack work in India?
When was BioStack founded?
Is BioStack backed by Y Combinator?
Where is BioStack based?
More in Funding
QwikBuild Raises $2.3 Million Led by Globalway
The Bengaluru AI startup has closed a pre-seed round and is forming a Japan joint venture.
dubdub Raises $1.3 Million in Seed Funding for Its Trivia App
The swipe-based trivia and puzzle app will hire in product and engineering and add new formats.
Clinics On Cloud Raises Rs 120 Crore in Series A From Model42
The Pune-based Health ATM maker raised its Series A at a valuation of Rs 600 crore.